Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: dlc who wrote (8831)	2/23/1999 10:47:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

First abstract: in Ulcerative Colitis seems to be auto antibodies as part of the cause of the disease. Anti-bpi antibodies is one of them, more so in the worst cases. This will create a lack of Bpi action and promote inflamatory changes. Potential? to replace bpi in this patients to regulate/eliminate inflamatory changes, Or to block the auto-antibodies so natural bpi could work. Xoma knows how to replace bpi, and they also know how to create monoclonal antibodies against specific bacteria (like the standby E5 research)or find the involved lymphocytes to be block (like the work in Psoriasis with GNE). 2nd abstract: This one showed bpi increasing in acute pancreatitis secondary to a procedure (endoscopic investigation of pancreas), probably here there is bacterial toxins involved and bpi rises to do the fight, more so in the more affected cases. Similar possibilities as in the First abstract, but a little more neboulous potential. Summary: from this two abstracts to an application if at all possible expect it several long years down the road, faster if bpi fda approval happens. Please, read this explanation as a rosy bias view about the subject from my part.